In:
Neuroendocrinology, S. Karger AG, Vol. 112, No. 12 ( 2022), p. 1187-1199
Abstract:
〈 b 〉 〈 i 〉 Introduction: 〈 /i 〉 〈 /b 〉 The RNA N6-methyladenosine (m6A) regulators play a crucial role in tumorigenesis and could be indicators of prognosis and therapeutic targets in various cancers. However, the expression status and prognostic value of m6A regulators have not been studied in pancreatic neuroendocrine neoplasms (PanNENs). We aimed to investigate the expression patterns and prognostic value of m6A regulators and assess their correlations with immune checkpoints and infiltrates in PanNENs. 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 Immunohistochemistry was performed for 15 m6A regulators and immune markers using tissue microarrays obtained from 183 patients with PanNENs. The correlation between m6A protein expression and clinicopathological parameters with recurrence-free survival (RFS) was examined using a random survival forest, Cox regression model, and survival tree analysis. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 Among the 15 m6A proteins, high expression of YTHDF2 ( 〈 i 〉 p 〈 /i 〉 & #x3c; 0.001) and HNRNPC ( 〈 i 〉 p 〈 /i 〉 = 0.006) was found to be significantly associated with recurrence and served as independent risk factors in multivariate analysis. High YTHDF2 expression was associated with higher number of CD3 〈 sup 〉 + 〈 /sup 〉 T cells ( 〈 i 〉 p 〈 /i 〉 = 0.003), whereas high HNRNPC expression was significantly correlated with the expression of PD-L1 ( 〈 i 〉 p 〈 /i 〉 = 0.039). A YTHDF2-based signature was determined, including five patterns from survival tree analysis: patients with the LN 〈 sub 〉 neg 〈 /sub 〉 YTHDF2 〈 sub 〉 high 〈 /sub 〉 signature had a 5-year RFS rate of 92.1%, whereas patients with LN 〈 sub 〉 pos 〈 /sub 〉 TumorSize 〈 sub 〉 ＜2.5 cm 〈 /sub 〉 signature had the worst 5-year RFS rate of 0% ( 〈 i 〉 p 〈 /i 〉 & #x3c; 0.001). The area under receiver operating characteristic curve was 0.870 (95% confidence interval: 0.762–0.915) for the YTHDF2-based signature. The C-index was 0.978, suggesting good discrimination ability; moreover, the risk score of recurrence served as an independent prognostic factor indicating shorter RFS. 〈 b 〉 〈 i 〉 Conclusions: 〈 /i 〉 〈 /b 〉 YTHDF2 appears to serve as a promising prognostic biomarker and therapeutic target. A YTHDF2-based signature can identify distinct subgroups, which may be helpful to strategize personalized postoperative monitoring.
Type of Medium:
Online Resource
ISSN:
0028-3835
,
1423-0194
Language:
English
Publisher:
S. Karger AG
Publication Date:
2022
detail.hit.zdb_id:
1483028-0
